Finzati - Logo
GNFTY logo

Genfit S.A.

GNFTY • Biotechnology
$8.95
▲ +0.35 (+4.07%)
Current price
EarningsLatest report: Jun 30, 2025
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$243.95M
Growth
0.4%
Cash Flow
2/5
Trend
Volatile
Evidence
Positive revenue growth · 186.9%Positive free cash flow · 0.28Manageable debt level · 0.9Expensive earnings multiple · 119.75
Financial data as of: Jun 30, 2025, 12:00 AM UTCLast earnings update: Jun 30, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$8.95
Change4.07%
Shares Out49.78M
Market Cap$243.95M
52W Range2.55 - 10.20
Beta1.19
P/E-2.17
P/S2.43
P/B1.64
P/FCF-2.77
EV/Sales5.32
EV/EBITDA197.85

Investment DNA

How strong this company looks for long-term investors

52
out of 100
Business Quality
Margins, moat, returns
40/100
Financial Strength
Debt, cash, stability
59/100
Growth Potential
Revenue and expansion
58/100
Price Attractiveness
Cheap or expensive today
64/100
Why this score▼
Positive revenue growth · 186.9%Positive free cash flow · 0.28Manageable debt level · 0.9Expensive earnings multiple · 119.75

Analyst view

Analyst sentiment and price target

GNFT
Analyst sentiment
Based on 7 analyst votes · 2026-09-04
86/100
Bullish
Bullish
6
Hold
0
Bearish
1
Price Target
2026-06-06
Low
$13.00
Mean
$13.00
Median
$13.00
High
$13.00

Company Overview

IPO: 3/27/2019
Industry: Biotechnology
P/B i: 1.64
Debt / Equity i: 0.90
Operating Margin: 4.90%
Net Margin: 2.25%
ROE i: -
ROIC: -

Financial Health

Score12 / 20
Debt / Equity: 0.90
Current Ratio: 1.23
Quick Ratio: 1.23
Status: Good
🧾

No insider activity

No recent insider transactions available.